NCT07141862 Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method
| NCT ID | NCT07141862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Neuroblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 89 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 89 participants in total. It began in 2025-02-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In prepubertal patients, cryopreservation of ovarian or testicular tissue is currently the only available method for fertility preservation prior to gonadotoxic cancer treatments. However, this approach carries the risk of reintroducing malignant cells upon autotransplantation, particularly in cases of metastatic cancers such as neuroblastoma and Ewing sarcoma. Therefore, it is crucial to employ highly sensitive techniques to detect minimal residual disease (MRD) in preserved gonadal tissues. This study aims to identify the most effective detection method by comparing the sensitivity and specificity of reverse transcription quantitative PCR (RT-qPCR) and droplet digital PCR (ddPCR) in identifying MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues from patients treated for these malignancies during infancy.
Eligibility Criteria
Inclusion Criteria: * Women of any age diagnosed with a benign cyst requiring laparoscopy may be included. * Men of any age diagnosed with a non-obstructive azoospermia may be included. * Prepubertal girls and boys diagnosed with neuroblastoma or Ewing sarcoma during infancy may be included. * Capable of providing written informed consent to participate in the research study * Affiliated with a social welfare service. * For prepubertal patients, written informed consent to participate in the research study must be provided by their parents or legal guardians. Exclusion Criteria: * None
Contact & Investigator
Florence BRUGNON, MD, PhD, HDR
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT07141862 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 45 Years, studying Neuroblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07141862 currently recruiting?
Yes, NCT07141862 is actively recruiting participants. Contact the research team at drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT07141862 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT07141862 clinical trial?
NCT07141862 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Florence BRUGNON, MD, PhD, HDR at University Hospital, Clermont-Ferrand. The trial plans to enroll 89 participants.